November 15, 2009 (Orlando, Florida) — Results for the first head-to-head comparison of different platelet-function tests suggests that a handful of platelet reactivity assays--used to test the ...

Approximately 40% of adolescent women experience heavy menstrual bleeding (HMB), and 10–62% of them have an underlying bleeding disorder (BD). Diagnosing a BD remains challenging because of ...

Against the backdrop of wide variability in thrombotic risk and clopidogrel response in patients following percutaneous coronary intervention (PCI) as well as growing use of more potent antiplatelet ...

The document follows two earlier consensus documents, released in 2013 and 2016. Dominick Angiolillo, MD, PhD (University of Florida College of Medicine – Jacksonville), senior author of the paper, ...

Managing drug dosage is critical to the overall success of pharmaceutical intervention, not only in the clinic but also in clinical trials. Inadequate dose management of certain drugs can have fatal ...

April 10, 2009 (Munich, Germany) — A new study using platelet-aggregometry testing to assess the effects of different proton-pump inhibitors (PPIs) on platelet response to clopidogrel suggests that ...

CHICAGO – Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine ...

What Is the Platelet Aggregation Test? A platelet aggregation test is a blood test that looks at how well your blood cells called platelets clump together and clot. It is sometimes called a platelet ...

Following Stent Placement, Low Platelet Reactivity at Time of Discharge and After 30 Days Leads to 50% Reduction in Cardiovascular Events "These new findings from GRAVITAS demonstrate that patients ...

While thrombocytopenia and bleeding are events that often occur together in neonates, this may not signify cause and effect. In fact, one study reported that 91% of neonates with low platelet counts ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...